These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17417100)

  • 1. High prevalence of subtherapeutic plasma concentrations of efavirenz in children.
    Ren Y; Nuttall JJ; Egbers C; Eley BS; Meyers TM; Smith PJ; Maartens G; McIlleron HM
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):133-6. PubMed ID: 17417100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.
    Ren Y; Nuttall JJ; Eley BS; Meyers TM; Smith PJ; Maartens G; McIlleron HM
    J Acquir Immune Defic Syndr; 2009 Apr; 50(5):439-43. PubMed ID: 19223781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania.
    Sungi SS; Ngaimisi E; Ulenga N; Sasi P; Mugusi S
    BMC Pharmacol Toxicol; 2018 Oct; 19(1):66. PubMed ID: 30352627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children.
    Viljoen M; Gous H; Kruger HS; Riddick A; Meyers TM; Rheeders M
    AIDS Res Hum Retroviruses; 2010 Jun; 26(6):613-9. PubMed ID: 20507205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.
    Wintergerst U; Hoffmann F; Jansson A; Notheis G; Huss K; Kurowski M; Burger D
    J Antimicrob Chemother; 2008 Jun; 61(6):1336-9. PubMed ID: 18343800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy.
    Pereira SA; Branco T; Caixas U; Côrte-Real RM; Germano I; Lampreia F; Monteiro EC
    Ther Drug Monit; 2008 Feb; 30(1):60-6. PubMed ID: 18223464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A validated method for simultaneous quantification of four antiretrovirals in dried blood spot and plasma using LC-MS/MS: Application to efavirenz therapeutic drug monitoring in pregnant patients.
    Ludna Duarte M; Mikaelle Brandão Silva A; Wellithom Viturino da Silva J; Pereira Santana D; Victor de Castro W; Cláudio Arraes de Alencar L; César Galindo Bedor D; Bastos Leal L
    Clin Biochem; 2024 May; 127-128():110765. PubMed ID: 38649089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.
    Bednasz CJ; Venuto CS; Ma Q; Daar ES; Sax PE; Fischl MA; Collier AC; Smith KY; Tierney C; Yang Y; Wilding GE; Morse GD
    Ther Drug Monit; 2017 Dec; 39(6):596-603. PubMed ID: 29135907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Nevirapine and Efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy.
    Shah I; Swaminathan S; Ramachandran G; Kumar AK; Goray A; Chaddha U; Tayal S; Lala M
    Indian Pediatr; 2011 Dec; 48(12):943-7. PubMed ID: 21555806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
    Hirt D; Urien S; Olivier M; Peyrière H; Nacro B; Diagbouga S; Zoure E; Rouet F; Hien H; Msellati P; Van De Perre P; Tréluyer JM
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4407-13. PubMed ID: 19635964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations.
    ter Heine R; Scherpbier HJ; Crommentuyn KM; Bekker V; Beijnen JH; Kuijpers TW; Huitema AD
    Antivir Ther; 2008; 13(6):779-87. PubMed ID: 18839779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines.
    von Hentig N; Koenigs C; Elanjikal S; Linde R; Dunsch D; Kreuz W; Funk MB
    Eur J Med Res; 2006 Sep; 11(9):377-80. PubMed ID: 17101460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals.
    Poeta J; Linden R; Antunes MV; Real L; Menezes AM; Ribeiro JP; Sprinz E
    J Antimicrob Chemother; 2011 Nov; 66(11):2601-4. PubMed ID: 21890538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
    Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
    Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms.
    Mutwa PR; Fillekes Q; Malgaz M; Tuyishimire D; Kraats Rv; Boer KR; Burger DM; van Schaik RH; Muganga N; Geelen SP
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):400-4. PubMed ID: 22481606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
    Best BM; Koopmans PP; Letendre SL; Capparelli EV; Rossi SS; Clifford DB; Collier AC; Gelman BB; Mbeo G; McCutchan JA; Simpson DM; Haubrich R; Ellis R; Grant I;
    J Antimicrob Chemother; 2011 Feb; 66(2):354-7. PubMed ID: 21098541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
    Marzolini C; Telenti A; Decosterd LA; Greub G; Biollaz J; Buclin T
    AIDS; 2001 Jan; 15(1):71-5. PubMed ID: 11192870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma efavirenz in HIV infected children treated with generic antiretroviral drugs in India.
    Ramachandran G; Kumar AK; Vasantha M; Shah I; Swaminathan S
    Indian Pediatr; 2010 Oct; 47(10):890-1. PubMed ID: 21048244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
    Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
    Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.